Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents
Authors:
- Xavier Saez-LlorensXSXavier Saez-Llorens
- Diana Catalina Aguilera VacaDVDiana Catalina Aguilera Vaca
- Katia AbarcaKAKatia Abarca
- Emmanuelle MahoEMEmmanuelle Maho
- Maria Gabriela GrañaMGMaria Gabriela Graña
- Esther HeijnenEHEsther Heijnen
- Igor SmolenovISIgor Smolenov
- Peter M DullPDPeter M Dull
- 6 April 2015
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 11 (6) , 1507-1517
Abstract
This phase 2 study assessed the immunogenicity, safety, and reactogenicity of investigational formulations of meningococcal ABCWY vaccines, consisting of recombinant proteins (rMenB) and outer membrane vesicle (OMV) components of a licensed serogroup B vaccine, combined with components of a licensed quadrivalent meningococcal glycoconjugate vaccine (MenACWY-CRM). A total of 495 healthy adolescents were randomized to 6 groups to receive 2 doses (Months 0, 2) of one of 4 formulations of rMenB antigens, with or without OMV, combined with MenACWY-CRM, or 2 doses of rMenB alone or one dose of MenACWY-CRM then a placebo. Immunogenicity was assessed by serum bactericidal assay with human complement (hSBA) against serogroups ACWY and serogroup B test strains; solicited reactions and any adverse events (AEs) were assessed. Two MenABCWY vaccinations elicited robust ACWY immune responses, with higher seroresponse rates than one dose of MenACWY-CRM. Bactericidal antibody responses against the rMenB antigens and OMV components were highest in subjects who received 2 doses of OMV-containing MenABCWY formulations, with ≥68% of subjects achieving hSBA titers ≥5 against each of the serogroup B test strains. After the first dose, solicited local reaction rates were higher in the MenABCWY or rMenB groups than the MenACWY-CRM group, but similar across groups after the second dose, consisting mainly of transient injection site pain. Fever (≥38.0°C) was rare and there were no vaccine-related serious AEs. In conclusion, investigational MenABCWY formulations containing OMV components elicited highly immunogenic responses against meningococcal serogroups ACWY, as well as serogroup B test strains, with an acceptable safety profile. [NCT01210885].Keywords
This publication has 35 references indexed in Scilit:
- Meningococcal Factor H Binding Proteins in Epidemic Strains from Africa: Implications for Vaccine DevelopmentPLOS Neglected Tropical Diseases, 2011
- Critical appraisal of a quadrivalent CRM197 conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo®) in the context of treatment and prevention of invasive diseaseInfection and Drug Resistance, 2011
- Development of an Automated, High-Throughput Bactericidal Assay That Measures Cellular Respiration as a Survival Readout for Neisseria meningitidisClinical and Vaccine Immunology, 2011
- Immunogenicity and Safety of a Multicomponent Meningococcal Serogroup B Vaccine and a Quadrivalent Meningococcal CRM 197 Conjugate Vaccine against Serogroups A, C, W-135, and Y in Adults Who Are at Increased Risk for Occupational Exposure to Meningococcal IsolatesClinical and Vaccine Immunology, 2011
- Immunogenicity of Two Investigational Serogroup B Meningococcal Vaccines in the First Year of LifeThe Pediatric Infectious Disease Journal, 2010
- Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccinesProceedings of the National Academy of Sciences, 2010
- The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiologyBMC Infectious Diseases, 2010
- Global epidemiology of meningococcal diseaseVaccine, 2009
- Meningococcal Factor H–Binding Protein Variants Expressed by Epidemic Capsular Group A, W‐135, and X Strains from AfricaThe Journal of Infectious Diseases, 2009
- A universal vaccine for serogroup B meningococcusProceedings of the National Academy of Sciences, 2006